ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Myotonic Dystrophy Drug Market Research Report 2024
Published Date: March 2024
|
Report Code: QYRE-Auto-26C9074
Home | Market Reports | Health| Pharmacy| Drugs & Medications
Global Myotonic Dystrophy Drug Market Insights and Forecast to 2028
BUY CHAPTERS

Global Myotonic Dystrophy Drug Market Research Report 2024

Code: QYRE-Auto-26C9074
Report
March 2024
Pages:86
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Lupin Ltd
TEVA
ANI Pharmaceuticals
Mylan NV
Novartis
Sun Pharma
Mallinckrodt plc

Myotonic Dystrophy Drug Market Size

The global Myotonic Dystrophy Drug market was valued at US$ 42 million in 2023 and is anticipated to reach US$ 67 million by 2030, witnessing a CAGR of 6.8% during the forecast period 2024-2030.

Myotonic Dystrophy Drug Market

Myotonic Dystrophy Drug Market

Myotonic dystrophy is a type of muscular dystrophy, a group of long-term genetic disorders that impair muscle function. Symptoms include gradually worsening muscle loss and weakness. Muscles often contract and are unable to relax. Other symptoms may include cataracts, intellectual disability and heart conduction problems. In men, there may be early balding and an inability to have children.
Myotonic dystrophy affects more than 1 in 8,000 people worldwide. While myotonic dystrophy can occur at any age, onset is typically in the 20s and 30s. It is the most common form of muscular dystrophy that begins in adulthood.
Drugs that have been used to treat myotonia include sodium channel blockers such as procainamide, phenytoin and mexiletine, tricyclic antidepressant drugs such as clomipramine or imipramine, benzodiazepines, calcium antagonists, taurine and prednisone.
The classification of Myotonic Dystrophy Drug includes Sodium Channel Blocker, Tricyclic Antidepressant and Other, and the sale proportion of Sodium Channel Blocker in 2019 is about 50%. Myotonic Dystrophy Drug is widely sold through Hospital Pharmacy, Retail Pharmacy, etc. The most proportion of Myotonic Dystrophy Drug sold through for Hospital Pharmacy, and the proportion in 2019 is nearly 45%. North America is the largest consumption place, with a consumption market share over 45% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 28%. Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.
This report aims to provide a comprehensive presentation of the global market for Myotonic Dystrophy Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myotonic Dystrophy Drug.

Report Scope

The Myotonic Dystrophy Drug market size, estimations, and forecasts are provided in terms of sales volume (K Unit) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Myotonic Dystrophy Drug market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myotonic Dystrophy Drug manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation

Scope of Myotonic Dystrophy Drug Market Report

Report Metric Details
Report Name Myotonic Dystrophy Drug Market
Accounted market size in 2023 US$ 42 million
Forecasted market size in 2030 US$ 67 million
CAGR 6.8%
Base Year 2023
Forecasted years 2024 - 2030
Segment by Type
  • Sodium Channel Blocker
  • Tricyclic Antidepressant
  • Other
Segment by Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy
  • Other
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, Sun Pharma, Mallinckrodt
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Myotonic Dystrophy Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Myotonic Dystrophy Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Myotonic Dystrophy Drug Market growing?

Ans: The Myotonic Dystrophy Drug Market witnessing a CAGR of 6.8% during the forecast period 2024-2030.

What is the Myotonic Dystrophy Drug Market size in 2030?

Ans: The Myotonic Dystrophy Drug Market size in 2030 will be US$ 67 million.

What is the Myotonic Dystrophy Drug Market share by region?

Ans: North America is the largest consumption place, with a consumption market share over 45% in 2019.

What is the Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis share in Myotonic Dystrophy Drug Market?

Ans: Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, etc. are the leaders of the industry, with totally about 60% market shares.

Who are the main players in the Myotonic Dystrophy Drug Market report?

Ans: The main players in the Myotonic Dystrophy Drug Market are Lupin, Teva, ANI Pharmaceuticals, Mylan, Novartis, Sun Pharma, Mallinckrodt

What are the Type segmentation covered in the Myotonic Dystrophy Drug Market report?

Ans: The Types covered in the Myotonic Dystrophy Drug Market report are Sodium Channel Blocker, Tricyclic Antidepressant, Other

1 Myotonic Dystrophy Drug Market Overview
1.1 Product Overview and Scope of Myotonic Dystrophy Drug
1.2 Myotonic Dystrophy Drug Segment by Type
1.2.1 Global Myotonic Dystrophy Drug Market Value Comparison by Type (2024-2030)
1.2.2 Sodium Channel Blocker
1.2.3 Tricyclic Antidepressant
1.2.4 Other
1.3 Myotonic Dystrophy Drug Segment by Distribution Channel
1.3.1 Global Myotonic Dystrophy Drug Market Value by Distribution Channel: (2024-2030)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Global Myotonic Dystrophy Drug Market Size Estimates and Forecasts
1.4.1 Global Myotonic Dystrophy Drug Revenue 2019-2030
1.4.2 Global Myotonic Dystrophy Drug Sales 2019-2030
1.4.3 Global Myotonic Dystrophy Drug Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Myotonic Dystrophy Drug Market Competition by Manufacturers
2.1 Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2019-2024)
2.2 Global Myotonic Dystrophy Drug Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Myotonic Dystrophy Drug Average Price by Manufacturers (2019-2024)
2.4 Global Myotonic Dystrophy Drug Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Myotonic Dystrophy Drug, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Myotonic Dystrophy Drug, Product Type & Application
2.7 Myotonic Dystrophy Drug Market Competitive Situation and Trends
2.7.1 Myotonic Dystrophy Drug Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Myotonic Dystrophy Drug Players Market Share by Revenue
2.7.3 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Myotonic Dystrophy Drug Retrospective Market Scenario by Region
3.1 Global Myotonic Dystrophy Drug Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Myotonic Dystrophy Drug Global Myotonic Dystrophy Drug Sales by Region: 2019-2030
3.2.1 Global Myotonic Dystrophy Drug Sales by Region: 2019-2024
3.2.2 Global Myotonic Dystrophy Drug Sales by Region: 2025-2030
3.3 Global Myotonic Dystrophy Drug Global Myotonic Dystrophy Drug Revenue by Region: 2019-2030
3.3.1 Global Myotonic Dystrophy Drug Revenue by Region: 2019-2024
3.3.2 Global Myotonic Dystrophy Drug Revenue by Region: 2025-2030
3.4 North America Myotonic Dystrophy Drug Market Facts & Figures by Country
3.4.1 North America Myotonic Dystrophy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Myotonic Dystrophy Drug Sales by Country (2019-2030)
3.4.3 North America Myotonic Dystrophy Drug Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Myotonic Dystrophy Drug Market Facts & Figures by Country
3.5.1 Europe Myotonic Dystrophy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Myotonic Dystrophy Drug Sales by Country (2019-2030)
3.5.3 Europe Myotonic Dystrophy Drug Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Country
3.6.1 Asia Pacific Myotonic Dystrophy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Myotonic Dystrophy Drug Sales by Country (2019-2030)
3.6.3 Asia Pacific Myotonic Dystrophy Drug Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Myotonic Dystrophy Drug Market Facts & Figures by Country
3.7.1 Latin America Myotonic Dystrophy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Myotonic Dystrophy Drug Sales by Country (2019-2030)
3.7.3 Latin America Myotonic Dystrophy Drug Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Country
3.8.1 Middle East and Africa Myotonic Dystrophy Drug Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2019-2030)
3.8.3 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Myotonic Dystrophy Drug Sales by Type (2019-2030)
4.1.1 Global Myotonic Dystrophy Drug Sales by Type (2019-2024)
4.1.2 Global Myotonic Dystrophy Drug Sales by Type (2025-2030)
4.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Type (2019-2030)
4.2 Global Myotonic Dystrophy Drug Revenue by Type (2019-2030)
4.2.1 Global Myotonic Dystrophy Drug Revenue by Type (2019-2024)
4.2.2 Global Myotonic Dystrophy Drug Revenue by Type (2025-2030)
4.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Type (2019-2030)
4.3 Global Myotonic Dystrophy Drug Price by Type (2019-2030)
5 Segment by Distribution Channel
5.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2019-2030)
5.1.1 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2019-2024)
5.1.2 Global Myotonic Dystrophy Drug Sales by Distribution Channel (2025-2030)
5.1.3 Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2019-2030)
5.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2019-2030)
5.2.1 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2019-2024)
5.2.2 Global Myotonic Dystrophy Drug Revenue by Distribution Channel (2025-2030)
5.2.3 Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2019-2030)
5.3 Global Myotonic Dystrophy Drug Price by Distribution Channel (2019-2030)
6 Key Companies Profiled
6.1 Lupin
6.1.1 Lupin Corporation Information
6.1.2 Lupin Description and Business Overview
6.1.3 Lupin Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Lupin Myotonic Dystrophy Drug Product Portfolio
6.1.5 Lupin Recent Developments/Updates
6.2 Teva
6.2.1 Teva Corporation Information
6.2.2 Teva Description and Business Overview
6.2.3 Teva Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Teva Myotonic Dystrophy Drug Product Portfolio
6.2.5 Teva Recent Developments/Updates
6.3 ANI Pharmaceuticals
6.3.1 ANI Pharmaceuticals Corporation Information
6.3.2 ANI Pharmaceuticals Description and Business Overview
6.3.3 ANI Pharmaceuticals Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.3.4 ANI Pharmaceuticals Myotonic Dystrophy Drug Product Portfolio
6.3.5 ANI Pharmaceuticals Recent Developments/Updates
6.4 Mylan
6.4.1 Mylan Corporation Information
6.4.2 Mylan Description and Business Overview
6.4.3 Mylan Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mylan Myotonic Dystrophy Drug Product Portfolio
6.4.5 Mylan Recent Developments/Updates
6.5 Novartis
6.5.1 Novartis Corporation Information
6.5.2 Novartis Description and Business Overview
6.5.3 Novartis Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Novartis Myotonic Dystrophy Drug Product Portfolio
6.5.5 Novartis Recent Developments/Updates
6.6 Sun Pharma
6.6.1 Sun Pharma Corporation Information
6.6.2 Sun Pharma Description and Business Overview
6.6.3 Sun Pharma Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Sun Pharma Myotonic Dystrophy Drug Product Portfolio
6.6.5 Sun Pharma Recent Developments/Updates
6.7 Mallinckrodt
6.6.1 Mallinckrodt Corporation Information
6.6.2 Mallinckrodt Description and Business Overview
6.6.3 Mallinckrodt Myotonic Dystrophy Drug Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Mallinckrodt Myotonic Dystrophy Drug Product Portfolio
6.7.5 Mallinckrodt Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Myotonic Dystrophy Drug Industry Chain Analysis
7.2 Myotonic Dystrophy Drug Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Myotonic Dystrophy Drug Production Mode & Process
7.4 Myotonic Dystrophy Drug Sales and Marketing
7.4.1 Myotonic Dystrophy Drug Sales Channels
7.4.2 Myotonic Dystrophy Drug Distributors
7.5 Myotonic Dystrophy Drug Customers
8 Myotonic Dystrophy Drug Market Dynamics
8.1 Myotonic Dystrophy Drug Industry Trends
8.2 Myotonic Dystrophy Drug Market Drivers
8.3 Myotonic Dystrophy Drug Market Challenges
8.4 Myotonic Dystrophy Drug Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Lupin Ltd
TEVA
ANI Pharmaceuticals
Mylan NV
Novartis
Sun Pharma
Mallinckrodt plc
List of Tables
    Table 1. Global Myotonic Dystrophy Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Table 2. Global Myotonic Dystrophy Drug Market Value Comparison by Distribution Channel (2024-2030) & (US$ Million)
    Table 3. Global Myotonic Dystrophy Drug Market Competitive Situation by Manufacturers in 2023
    Table 4. Global Myotonic Dystrophy Drug Sales (K Unit) of Key Manufacturers (2019-2024)
    Table 5. Global Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2019-2024)
    Table 6. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Manufacturers (2019-2024)
    Table 7. Global Myotonic Dystrophy Drug Revenue Share by Manufacturers (2019-2024)
    Table 8. Global Market Myotonic Dystrophy Drug Average Price (USD$/Unit) of Key Manufacturers (2019-2024)
    Table 9. Global Key Players of Myotonic Dystrophy Drug, Industry Ranking, 2022 VS 2023 VS 2024
    Table 10. Global Key Manufacturers of Myotonic Dystrophy Drug, Manufacturing Sites & Headquarters
    Table 11. Global Key Manufacturers of Myotonic Dystrophy Drug, Product Type & Application
    Table 12. Global Key Manufacturers of Myotonic Dystrophy Drug, Date of Enter into This Industry
    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Myotonic Dystrophy Drug as of 2023)
    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 16. Global Myotonic Dystrophy Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Table 17. Global Myotonic Dystrophy Drug Sales by Region (2019-2024) & (K Unit)
    Table 18. Global Myotonic Dystrophy Drug Sales Market Share by Region (2019-2024)
    Table 19. Global Myotonic Dystrophy Drug Sales by Region (2025-2030) & (K Unit)
    Table 20. Global Myotonic Dystrophy Drug Sales Market Share by Region (2025-2030)
    Table 21. Global Myotonic Dystrophy Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 22. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2019-2024)
    Table 23. Global Myotonic Dystrophy Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 24. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2025-2030)
    Table 25. North America Myotonic Dystrophy Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 26. North America Myotonic Dystrophy Drug Sales by Country (2019-2024) & (K Unit)
    Table 27. North America Myotonic Dystrophy Drug Sales by Country (2025-2030) & (K Unit)
    Table 28. North America Myotonic Dystrophy Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 29. North America Myotonic Dystrophy Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 30. Europe Myotonic Dystrophy Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 31. Europe Myotonic Dystrophy Drug Sales by Country (2019-2024) & (K Unit)
    Table 32. Europe Myotonic Dystrophy Drug Sales by Country (2025-2030) & (K Unit)
    Table 33. Europe Myotonic Dystrophy Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 34. Europe Myotonic Dystrophy Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 35. Asia Pacific Myotonic Dystrophy Drug Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 36. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2019-2024) & (K Unit)
    Table 37. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2025-2030) & (K Unit)
    Table 38. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 39. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 40. Latin America Myotonic Dystrophy Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 41. Latin America Myotonic Dystrophy Drug Sales by Country (2019-2024) & (K Unit)
    Table 42. Latin America Myotonic Dystrophy Drug Sales by Country (2025-2030) & (K Unit)
    Table 43. Latin America Myotonic Dystrophy Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 44. Latin America Myotonic Dystrophy Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 45. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 46. Middle East & Africa Myotonic Dystrophy Drug Sales by Country (2019-2024) & (K Unit)
    Table 47. Middle East & Africa Myotonic Dystrophy Drug Sales by Country (2025-2030) & (K Unit)
    Table 48. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 49. Middle East & Africa Myotonic Dystrophy Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 50. Global Myotonic Dystrophy Drug Sales (K Unit) by Type (2019-2024)
    Table 51. Global Myotonic Dystrophy Drug Sales (K Unit) by Type (2025-2030)
    Table 52. Global Myotonic Dystrophy Drug Sales Market Share by Type (2019-2024)
    Table 53. Global Myotonic Dystrophy Drug Sales Market Share by Type (2025-2030)
    Table 54. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Type (2019-2024)
    Table 55. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Type (2025-2030)
    Table 56. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2019-2024)
    Table 57. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2025-2030)
    Table 58. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2019-2024)
    Table 59. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2025-2030)
    Table 60. Global Myotonic Dystrophy Drug Sales (K Unit) by Distribution Channel (2019-2024)
    Table 61. Global Myotonic Dystrophy Drug Sales (K Unit) by Distribution Channel (2025-2030)
    Table 62. Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2019-2024)
    Table 63. Global Myotonic Dystrophy Drug Sales Market Share by Distribution Channel (2025-2030)
    Table 64. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Distribution Channel (2019-2024)
    Table 65. Global Myotonic Dystrophy Drug Revenue (US$ Million) by Distribution Channel (2025-2030)
    Table 66. Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2019-2024)
    Table 67. Global Myotonic Dystrophy Drug Revenue Market Share by Distribution Channel (2025-2030)
    Table 68. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2019-2024)
    Table 69. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2025-2030)
    Table 70. Lupin Corporation Information
    Table 71. Lupin Description and Business Overview
    Table 72. Lupin Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 73. Lupin Myotonic Dystrophy Drug Product
    Table 74. Lupin Recent Developments/Updates
    Table 75. Teva Corporation Information
    Table 76. Teva Description and Business Overview
    Table 77. Teva Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 78. Teva Myotonic Dystrophy Drug Product
    Table 79. Teva Recent Developments/Updates
    Table 80. ANI Pharmaceuticals Corporation Information
    Table 81. ANI Pharmaceuticals Description and Business Overview
    Table 82. ANI Pharmaceuticals Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 83. ANI Pharmaceuticals Myotonic Dystrophy Drug Product
    Table 84. ANI Pharmaceuticals Recent Developments/Updates
    Table 85. Mylan Corporation Information
    Table 86. Mylan Description and Business Overview
    Table 87. Mylan Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 88. Mylan Myotonic Dystrophy Drug Product
    Table 89. Mylan Recent Developments/Updates
    Table 90. Novartis Corporation Information
    Table 91. Novartis Description and Business Overview
    Table 92. Novartis Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 93. Novartis Myotonic Dystrophy Drug Product
    Table 94. Novartis Recent Developments/Updates
    Table 95. Sun Pharma Corporation Information
    Table 96. Sun Pharma Description and Business Overview
    Table 97. Sun Pharma Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 98. Sun Pharma Myotonic Dystrophy Drug Product
    Table 99. Sun Pharma Recent Developments/Updates
    Table 100. Mallinckrodt Corporation Information
    Table 101. Mallinckrodt Description and Business Overview
    Table 102. Mallinckrodt Myotonic Dystrophy Drug Sales (K Unit), Revenue (US$ Million), Price (USD$/Unit) and Gross Margin (2019-2024)
    Table 103. Mallinckrodt Myotonic Dystrophy Drug Product
    Table 104. Mallinckrodt Recent Developments/Updates
    Table 105. Key Raw Materials Lists
    Table 106. Raw Materials Key Suppliers Lists
    Table 107. Myotonic Dystrophy Drug Distributors List
    Table 108. Myotonic Dystrophy Drug Customers List
    Table 109. Myotonic Dystrophy Drug Market Trends
    Table 110. Myotonic Dystrophy Drug Market Drivers
    Table 111. Myotonic Dystrophy Drug Market Challenges
    Table 112. Myotonic Dystrophy Drug Market Restraints
    Table 113. Research Programs/Design for This Report
    Table 114. Key Data Information from Secondary Sources
    Table 115. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Myotonic Dystrophy Drug
    Figure 2. Global Myotonic Dystrophy Drug Market Value Comparison by Type (2024-2030) & (US$ Million)
    Figure 3. Global Myotonic Dystrophy Drug Market Share by Type in 2023 & 2030
    Figure 4. Sodium Channel Blocker Product Picture
    Figure 5. Tricyclic Antidepressant Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Myotonic Dystrophy Drug Market Value Comparison by Distribution Channel (2024-2030) & (US$ Million)
    Figure 8. Global Myotonic Dystrophy Drug Market Share by Distribution Channel in 2023 & 2030
    Figure 9. Hospital Pharmacy
    Figure 10. Retail Pharmacy
    Figure 11. Other
    Figure 12. Global Myotonic Dystrophy Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 13. Global Myotonic Dystrophy Drug Market Size (2019-2030) & (US$ Million)
    Figure 14. Global Myotonic Dystrophy Drug Sales (2019-2030) & (K Unit)
    Figure 15. Global Myotonic Dystrophy Drug Average Price (USD$/Unit) & (2019-2030)
    Figure 16. Myotonic Dystrophy Drug Report Years Considered
    Figure 17. Myotonic Dystrophy Drug Sales Share by Manufacturers in 2023
    Figure 18. Global Myotonic Dystrophy Drug Revenue Share by Manufacturers in 2023
    Figure 19. The Global 5 and 10 Largest Myotonic Dystrophy Drug Players: Market Share by Revenue in 2023
    Figure 20. Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
    Figure 21. Global Myotonic Dystrophy Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
    Figure 22. North America Myotonic Dystrophy Drug Sales Market Share by Country (2019-2030)
    Figure 23. North America Myotonic Dystrophy Drug Revenue Market Share by Country (2019-2030)
    Figure 24. U.S. Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 25. Canada Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 26. Europe Myotonic Dystrophy Drug Sales Market Share by Country (2019-2030)
    Figure 27. Europe Myotonic Dystrophy Drug Revenue Market Share by Country (2019-2030)
    Figure 28. Germany Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 29. France Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 30. U.K. Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 31. Italy Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 32. Russia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 33. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Region (2019-2030)
    Figure 34. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Region (2019-2030)
    Figure 35. China Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 36. Japan Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 37. South Korea Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 38. India Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 39. Australia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 40. Taiwan Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 41. Indonesia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 42. Thailand Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 43. Malaysia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 44. Latin America Myotonic Dystrophy Drug Sales Market Share by Country (2019-2030)
    Figure 45. Latin America Myotonic Dystrophy Drug Revenue Market Share by Country (2019-2030)
    Figure 46. Mexico Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 47. Brazil Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 48. Argentina Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 49. Colombia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 50. Middle East & Africa Myotonic Dystrophy Drug Sales Market Share by Country (2019-2030)
    Figure 51. Middle East & Africa Myotonic Dystrophy Drug Revenue Market Share by Country (2019-2030)
    Figure 52. Turkey Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 53. Saudi Arabia Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 54. UAE Myotonic Dystrophy Drug Revenue Growth Rate (2019-2030) & (US$ Million)
    Figure 55. Global Sales Market Share of Myotonic Dystrophy Drug by Type (2019-2030)
    Figure 56. Global Revenue Market Share of Myotonic Dystrophy Drug by Type (2019-2030)
    Figure 57. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Type (2019-2030)
    Figure 58. Global Sales Market Share of Myotonic Dystrophy Drug by Distribution Channel (2019-2030)
    Figure 59. Global Revenue Market Share of Myotonic Dystrophy Drug by Distribution Channel (2019-2030)
    Figure 60. Global Myotonic Dystrophy Drug Price (USD$/Unit) by Distribution Channel (2019-2030)
    Figure 61. Myotonic Dystrophy Drug Value Chain
    Figure 62. Myotonic Dystrophy Drug Production Process
    Figure 63. Channels of Distribution (Direct Vs Distribution)
    Figure 64. Distributors Profiles
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Strategic Venue Partners

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions